Drug Delivery Fee

No definition available.

Name:	ivvd_DrugDeliveryFee
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Due From Related Party

+ References

No definition available.

+ Details

Name:	ivvd_DueFromRelatedParty
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Due To Related Parties

+ References

No definition available.

+ Details

Name:	ivvd_DueToRelatedParties
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Preferred Stock, Fair Value.

+ References

No definition available.

+ Details

Name:	ivvd_PreferredStockFairValue
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Quarterly Fee.

+ References

No definition available.

+ Details

Name:	ivvd_QuarterlyFee
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Related Party Transaction Expenses From Transaction With Related Party

+ References

No definition available.

+ Details

Name:	ivvd_RelatedPartyTransactionExpensesFromTransactionWithRelatedParty
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_PreferredStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=ivvd_InProcessResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_AdimabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_AdimabAssignmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_AdimabCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_AdimabPlatformTransferAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_MithrilGroupMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_PhpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jul. 31, 2021	Apr. 30, 2021	Nov. 30, 2020	Jul. 31, 2020
Related Party Transaction [Line Items]
Preferred stock shares issued	0	0	16,944,484
Quarterly Fee	$ 1,300
Research and Development Expense [Member]
Related Party Transaction [Line Items]
Quarterly Fee	5,200	$ 2,600
Series B Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock shares issued					1,410,434
Series C preferred stock [Member]
Related Party Transaction [Line Items]
Preferred stock shares issued				4,296,550
Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock shares issued						6,237,500
Related Party [Member] \| In Process Research And Development Expense [Member]
Related Party Transaction [Line Items]
Expense due to releted party	1,000	0
Related Party [Member] \| Research and Development Expense [Member]
Related Party Transaction [Line Items]
Drug Delivery Fee	$ 400	0
Adimab [Member] \| Series B Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares issued	44,076
Purchase price of shares	$ 2,500
Adimab [Member] \| Series C preferred stock [Member]
Related Party Transaction [Line Items]
Number of shares issued	128,064
Purchase price of shares	$ 10,000
Adimab Assignment Agreement [Member]
Related Party Transaction [Line Items]
Preferred stock shares issued						5,000,000
Due To Related Parties	300	600
Due From Related Party	0	0
Adimab Assignment Agreement [Member] \| In Process Research And Development Expense [Member]
Related Party Transaction [Line Items]
Expense due to releted party	0	7,500
Adimab Assignment Agreement [Member] \| Research and Development Expense [Member]
Related Party Transaction [Line Items]
Expense due to releted party	600	1,300
Adimab Assignment Agreement [Member] \| Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock shares issued						5,000,000
Preferred Stock Fair Value						$ 40,000
Adimab Collaboration Agreement [Member] \| Research and Development Expense [Member]
Related Party Transaction [Line Items]
Quarterly Fee	5,200	2,600
Expense due to releted party	1,700	$ 300
Adimab Platform Transfer Agreement [Member] \| In Process Research And Development Expense [Member]
Related Party Transaction [Line Items]
Expense due to releted party	3,000
Mithril Group [Member]
Related Party Transaction [Line Items]
Due To Related Parties	0
Mithril Group [Member] \| Research and Development Expense [Member]
Related Party Transaction [Line Items]
Expense due to releted party	1,400
PHP Member
Related Party Transaction [Line Items]
Due To Related Parties	800
Due From Related Party	0
PHP Member \| Warrant [Member]
Related Party Transaction [Line Items]
Expense due to releted party	17,400
PHP Member \| Research and Development Expense [Member]
Related Party Transaction [Line Items]
Expense due to releted party	$ 800